Gout is now the most common cause of inflammatory arthritis, and its epidemiology worldwide points to an increase in incidence and prevalence in both developed and developing countries 1 . Gout is caused by hyper uricaemia (serum urate levels >7 mg/l (420 μmol/l)) lead ing to the formation and deposition of monosodium urate (MSU) crystals. Clinically, the disease is characterized by acute episodes of joint inflammation, usually affecting a single joint, interspersed with symptomfree periods of variable duration. If untreated, gout typically progresses to the formation of urate deposits (tophi) in soft tissues, recurrent attacks of arthritis affecting multiple joints and progressive joint destruction. Other complications include renal deposits of uric acid that can provoke renal failure and the formation of renal stones. These and other clinical features have been reviewed elsewhere 2 . Gout is now regarded as a prototypical inflamma tory disease driven by activation of the innate immune system. Gout has also been termed an autoinflammatory disease 3 ; however, this classification is misleading as, unlike hereditary autoinflammatory diseases, the acute trigger of gout is MSU crystals. Uric acid itself is an endo genous and ubiquitous metabolite that is not considered to be proinflammatory, and MSU crystal formation is required to provoke clinically observed inflammation.
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The study of the underlying mechanisms of gouty inflammation has led to remarkable insights into the con trol of the inflammasome and proinflammatory cytokine release. Nevertheless, we must bear in mind some of the other distinguishing features of gout: firstly, that the attack is usually selflimiting and, secondly, that MSU crystals can be present without an inflammatory response. These observations suggest that regulatory mechanisms exists that modify the acute inflammatory response, and a thorough understanding of pro inflammatory as well as antiinflammatory pathways could help to develop new strategies for the treatment of gout. In this Review, we discuss advances over the past decade in the field of gout inflammation research and emerging therapeutic strategies to manage acute gout attacks.
Uric acid-mediated inflammation
IL1β-mediated inflammation is a key aspect of gouty inflammation. In gout, IL1β production is mediated by MSU crystals triggering the inflammasome, a multi molecular complex whose dysregulation is central to many pathological inflammatory conditions.
Inflammasome activation by MSU crystals
MSU crystals trigger an inflammatory response from macrophages. The crystals are first taken up by macro phages and promote the assembly and activation of the NLRP3 inflammasome 4 . Inflammasomes are cytosolic multiprotein complexes that can initiate inflammatory responses 5, 6 . Inflammasomes assemble when cytosolic pattern recognition receptors (PRRs) such as NLRP3 sense acti vating signals that have reached the cytosol of the cell. This signalling leads to the oligomerization of the PRR and its recruitment to a complex of adaptor proteins and effector enzymes (FIG. 1) . NLRP3 inflammasomes are formed by the recruitment of the adaptor protein ASC and subsequent recruitment of caspase1. Following initial oligomerization within the inflammasome, ASC monomers can further autoassemble into high molecularweight oligomers. This process, referred to as 'prionlike' polymerization, amplifies the signals sensed by the PRR and engages virtually all ASC molecules into one active cellular complex 7 . Recruitment and oligo merization of caspase1 by this structure leads to the activation and proteolytic processing of its substrates.
Caspase1 activates the proinflammatory cytokines IL1β and IL18 by cleaving their respective pre cursor proteins, proIL1β and proIL18. In gout, inflammasome mediated IL1βrelease triggers an impor tant inflammatory response, with vasodilatation and rapid recruitment of neutrophils to the site of crystal deposition, and thereby drives acute inflammatory episodes 8 . Additional caspase1 substrates, such as gasdermins, are emerging as downstream targets of inflammasome engagement 9 . Gasdermins promote cell death upon the activation of inflammatory caspases 10, 11 . Caspase1 and caspase11 can cleave gasdermin D to release its Nterminal portion that then polymerizes at the plasma membrane, forming cytotoxic pores. These pores alter cellular integrity and result in cell death by pyroptosis, which is mediated by inflammatory caspases and differs from cell death mediated by apoptotic caspases in that it results in the release of the cytosolic contents of cells, including a plethora of proinflammatory mediators and danger signals. Pyroptosis can therefore amplify the inflammatory response and facilitate the release of cytokines, including IL1β. Whether this pathway con tributes to inflammation in gout remains to be estab lished. Uric acid crystals have also been proposed to trigger necroptosis, another proinflammatory type of cell death that is mediated by the activation of the receptorinteracting serine/threonineprotein kinase 3 (RIPK3) and mixed lineage kinase domainlike protein (MLKL) pathways 12 . Interestingly, disruption of cellular integrity during necroptosis can elicit NLRP3 inflamma some assembly 13 . Thus, necroptosis and pyroptosis might cooperate to amplify the release of inflammatory mediators in gout.
Mechanisms of inflammasome engagement
Despite the fact that activation of IL1β production and the role of the NLRP3 inflammasome in gout is well described, the upstream pathway that links MSU crystals to NLRP3 activation is poorly understood. Inflammasome engagement can be dissected into two prerequisite steps: priming and activation. Reliance on two signals is a key feature of most inflammasomes and increases the speci ficity of the response while avoiding inappropriate firing of the pathway. In gout, the nature of signal 1 is unclear but might rely on the activation of Tolllike receptors (TLRs) 14 . Signal 2 is provided by the interaction of MSU crystals with inflammasomecompetent cells 15 .
Signal 1 of inflammasome engagement primes cells for inflammasome assembly. Priming of the cell, also known as signal 1 16 , controls the expression of all components required for the assembly and activation of the inflam masome and contributes to the expression of the pre cursor proteins that are the substrates of inflammatory caspases. This inflammasomecompetent stage, which is achieved as a result of an inflammatory milieu, can orig inate by the engagement of innate immune receptors on the cell surface or as part of an autoamplification loop via IL1β itself.
Signalling pathways mediated by cellsurface recep tors coordinate the innate immune response. The best known of these receptors are the TLR family, of which TLR2 and TLR4 in particular have been implicated in gouty inflammation. Work published in 2005 showed that mice deficient in TLR2 or TLR4 have an impaired neutrophil response to MSU crystals in the airpouch model of gout 14 . A direct interaction between MSU crys tals and the TLRs was postulated, as macrophages defi cient for these receptors did not take up MSU crystals as efficiently as wildtype macrophages; however, no clear evidence demonstrated that MSU crystals could directly activate TLRs. Subsequent data suggested that TLRs regulate gouty inflammation by recognition of ligands that prime monocytes and macro phages to produce proIL1β. Proteins S100A8 and S100A9 are endo genous ligands of TLR4 and are secreted upon activa tion of phagocytes. Patients with gout and mice injected with MSU crystals produced high levels of S100A8 and S100A9, and genetic deletion of S100A9 reduced the response to MSU crystals in mice 17 . Another TLR ligand that might have a role in macrophage priming in gout is longchain free fatty acids (FFAs). In a murine model of gout, arthritis was only observed when mice were injected with both longchain FFAs and MSU crystals, whereas injection of MSU alone or longchain FFAs alone was not sufficient to elicit inflammation. Furthermore, it was demonstrated that TLR2 is the receptor that mediated the effects of longchain FFAs on macrophages 18 . The mechanisms by which TLRs can regulate inflammation have been reviewed elsewhere 19 .
Other factors such as granulocytemacrophage colony stimulating factor (GMCSF) and the comple ment protein C5a have been proposed to affect cell prim ing in gout. In monocytes from GMCSFneutralized mice, decreased levels of IL1β were observed following
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Signal 2 catalyses inflammasome assembly. A second signal, signal 2, is required for inflammasome activation. This signal is more specific than signal 1 and directly drives posttranscriptional and translational aggregation and polymerization of inflammasome components. The mechanisms by which MSU crystals trigger signal 2 to promote NLRP3 activation are still poorly understood. However, several steps commonly found upstream of NLRP3 activation are involved.
Perturbation of cellular ionic balances, in particular potassium efflux and calcium influx, is a characteristic feature of NLRP3 inducers 22, 23 . This ionic perturbation is necessary for the generation of mitochondrial reactive oxygen species (ROS) upstream of NLRP3 inflamma some assembly. ROS production is also an essential step for inflammasome formation, and is increased by MSU mediated leukotriene B4 (REF. 24 ) and might contribute to engage Nek7, a member of the family of mammalian NIMArelated Ser/Thr (Nek) kinases. Nek7 directly binds NLRP3 and could be the common NLRP3activating ligand [25] [26] [27] . How Nek7 interacts with NLRP3 and the mechanisms by which MSU crystals promote the ionic changes that ultimately engage the NLRP3activating cascade are important unanswered questions.
Mediators of the inflammatory response IL-1β is a key cytokine in gout
IL1β is a cytokine that acts on multiple cell types to elicit inflammatory responses 28 . Promotion of vaso dilatation by IL1β leads to the recruitment of monocytes and The interaction of MSU crystals with the plasma membrane promotes a cellular response that is still poorly understood but includes hallmarks of NLRP3 activation, including potassium efflux through ion channels and mitochondrial perturbations leading to the production and release of mitochondrial reactive oxygen species (ROS) into the cytosol. NLRP3-activating factors such as the mammalian NIMA-related Ser/Thr (Nek) kinase Nek7 are then engaged, promoting NLRP3 oligomerization and inflammasome assembly. The adaptor protein ASC is recruited to the inflammasome and nucleates into prion-like filaments. Caspase-1 is recruited by ASC and oligomerizes along the ASC filaments, leading to the autoproteolytic activation of caspase-1. Active caspase-1 then promotes the proteolytic cleavage and maturation of pro-IL-1β into biologically active IL-1β. Caspase-1 also promotes the cleavage of gasdermin D to generate an N-terminal cleavage product that oligomerizes at the plasma membrane, causing the formation of pyroptotic pores. These pores disrupt the integrity of the cellular plasma membrane, and might contribute to the release of inflammatory mediators including IL-1β. Inflammasome activation neutrophils to sites of tissue insults, a response that is crucial in combating infection and restoring tissue homeostasis. However, sustained IL1β secretion can result in the production of matrixdegrading enzymes that break down cartilage and bone 29 . At the systemic level, IL1β elicits a fever response by acting directly on the hypothalamic temperatureregulation centre 30 .
IL1β is mainly produced by innate immune cells and signals to target cells by binding to IL1 receptor type 1 (IL1R1). Once activated, IL1R1 and its coreceptor IL1 receptor accessory protein (IL1RAcP) recruit a signalling complex that shares components with TLR signalling pathways, leading to the activation of pro inflammatory transcription factors including nuclear factorκB (NFκB) as well as p38 cJun Nterminal kinase (JNK) (FIG. 2) . These transcription factors in turn promote the transcriptional upregulation of chemokines and proinflammatory mediators that orchestrate the IL1mediated inflammatory response.
Although inflammasome activation is the best char acterized mechanism leading to IL1β maturation in gout, it should be noted that, in addition to inflammatory caspases, other proteases can contribute to IL1 matura tion 31 . In the absence of the inflammasome, neutrophils can process proIL1β by the activity of neutrophil derived serine proteases such as proteinase3 (PR3, also known as myeloblastin), neutrophil elastase and cathepsin G 31, 32 . Other serine proteases can also process IL1β 33 . Some metallo proteinases and granzyme A have also been proposed to trigger the proteolytic activation of IL1β 34, 35 . Whether these pathways function to amplify the inflammatory reaction, for example in tissues with robust neutrophil recruitment, or as backup mechanisms that maintain IL1β production in conditions in which inflammasome proteins are absent or inhibited, is unclear.
Although it is now widely accepted that IL1β is a pivotal cytokine in acute gout 15 , a role for IL1α cannot be ruled out. IL1α is released during crystalinduced inflammation, and mice with deletion of the Il1b gene are still capable of mounting a neutrophil response 36 . The clinical relevance of IL1 is supported by data from a number of different studies of IL1 inhibition 37 . The clin ical experience with different IL1 inhibitors, including the antiIL1β monoclocal antibody canakinumab and the synthetic IL1 receptor antagonist (IL1Ra) anakinra, in the treatment of gout is detailed in a later section.
Other contributing cytokines IL8, also known as CXCchemokine ligand 8, is a macrophage secreted chemokine that acts principally on neutrophils. In a study published in 2015, data from three different cohorts of patients with gout showed that circulating levels of IL8 were increased during the acute phase of gout and, interestingly, also during the inter critical phase of gout (that is, the interval between flares); high circulating levels of IL8 also predicted concomitant diabetes mellitus in patients with gout. By contrast, other comorbidities that are commonly seen in gout (such as cardiovascular disease and chronic kidney disease) were not significantly associated with high IL8 levels 38 . The mechanisms underlying these observations have not yet been elucidated, but suggest that neutrophil recruitment and neutrophil activation are key inflammatory pathways.
Soluble uric acid
In gout, it is the formation of MSU crystals that trig gers acute inflammation, but data show that hyper uricaemia can also modulate the inflammatory response. Hyperuricaemia in the absence of MSU crystals is able to skew the leukocyte response towards an inflammatory pattern through epigenetic modifications such as histone methylation 39 . In patients with hyperuricaemia, this effect was shown by the enhanced production of IL1β and IL6, and the concomitant reduction of IL1Ra release 39 .
Dietary factors and the microbiome
Clinical observations indicate that dietary factors have a major role in gout, and the link between patterns of food consumption and hyperuricaemia and gout has long been established 40 . Moreover, the role of particular foods in triggering an acute attack has been raised, and findings from an Internetbased survey suggest that a purinerich diet increases the risk of an acute attack of gout fivefold 41 . However, which components of food are responsible and how they can lead to an attack remains to be determined. As mentioned earlier, longchain (C18) FFAs might have a role in priming macrophages to release IL1β upon phagocytosis of MSU crystals 18 . The gut microbiome and how this affects inflamma tion has been increasingly studied in the past few years. Using a mouse model of gout, Viera et al. showed that germfree mice showed attenuated MSU crystalinduced inflammation and that this effect was reproduced by anti biotic treatment. They also showed that these effects were mediated by acetate, a shortchain FFA that is released by gut bacteria. Acetate acts via the macrophage receptor FFA receptor 2 (also known as GPR43) to modulate inflam masome activation and IL1β production. Restoring the normal gut flora in germfree mice, or the administration of acetate, restored the inflammatory effects 42 . The same group further showed that a highfibre diet can attenuate arthritis severity in the same murine model of gout 43 . In this study, the increased production of acetate and other shortchain fatty acids resulting from the highfibre diet was proposed to regulate the resolution of inflammation, possibly by affecting neutrophils 43 . These studies suggest that environmental factors such as microbial metabolites can differentially regulate the cell types and pathways involved in gouty inflammation. Changes in the micro biome in patients with gout have not been extensively studied; however, in one report, the bacterial flora of patients with gout was different from that of healthy indi viduals and similar to that of patients with type 2 diabetes mellitus 44 . These findings need to be reproduced in larger cohorts before we can draw clear conclusions on how the microbiome modulates inflammation in gout.
Although interest in using diet to modulate hyper uricaemia is high, its overall effect is modest 45 . However, dietary factors might influence gouty inflammation. Clinical data from a study published in 2016 suggest that higher dietary consumption of omega3 fatty acids is associated with a lower frequency of acute gout flares 46 . Experimentally, omega3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) can inhibit NLRP3 inflammasome activation via a pathway that involves βarrestin2 and the Gprotein coupled receptors FFA receptor 4 (GPR120) and FFA receptor 1 (GPR40) 47 . These findings require confirmation by intervention trials using omega3 fatty acids in patients with gout.
Genetics of gouty inflammation
Genetic studies, including genomewide association studies (GWAS), have identified dozens of suscepti bility loci associated with hyperuricaemia and gout 48 . These loci mostly influence uric acid levels by affecting pathways such as renal and gut excretion of uric acid. Although hyperuricaemia might influence oxidative stress and thereby have some effect on inflammatory path ways, whether polymorphisms associated with hyper uricaemia and gout directly modulate inflammatory responses, beyond promoting uric acid crystallization, remains to be demonstrated.
Two studies demonstrated an association between gout and functional variants in the gene encoding caspase recruitment domaincontaining protein 8 (CARD8) 49, 50 . CARD8 is a potential negative regulator of the NLRP3 inflammasome; therefore, it is possible that these polymorphisms might increase inflammas ome activity and thereby contribute to the intensity or duration of NLRP3 engagement in gouty episodes. In addition, there is genetic evidence for a role for TLR4 in gout. Employing a candidategene approach, two studies, one performed in a Han Chinese population and the other in patients of European ancestry, found an association between the same genetic polymorphism of the TLR4 gene (rs2149356) and gout 51, 52 . These poly morphisms might affect the priming phase of inflam masome engagement or might have a broader effect on the inflammatory responses in these patients.
Another study linked gout incidence with a poly morphism within the PPARGC1B gene, encoding peroxisome proliferatoractivated receptor γ (PPARγ) co activator 1β 53 , which increased NLRP3 and IL1β expres sion. Because PPARγ coactivator 1β functions as a regulator of PPARγ, a master regulator of metabolism, this genetic evidence might link metabolic deregulation with gouty inflammation.
Resolution of inflammation
Monocytes and macrophages are the major cellular sources of IL1, but at the site of inflammation neu trophils predominate. The major proinflammatory role of the neutrophil and the mechanisms of interac tion between MSU crystals and the neutrophil have been reviewed elsewhere 54 . Interestingly, neutrophils probably also have a major role in the resolution of acute gout, through the formation of neutrophil extra cellular traps (NETs). This process is favoured at high concentrations of neutrophils in experimental settings (>10 × 10 6 cells per ml), and results in the formation of cellular aggregates that contain cellular debris and DNA, as well as neutrophil proteases released into the NETs 55 . NET formation is dependent on the generation of ROS, and molecules that regulate necroptosis via the RIPK3 pathway have also been implicated 56 . In the absence of RIPK3, NET formation was inhibited completely 56 . Once formed, cellular aggregates containing NETs can rapidly degrade a wide range of proinflammatory cytokines and, in experimental models, the inhibition of NET for mation results in severe and persistent gouty inflamma tion, whereas joint inflammation spontaneously resolves after 3 days when NET formation is not impaired 55 . These results show that neutrophils have a dual role in gouty inflammation: in the initial phase, when inflam mation is amplified by recruited neutrophils, and in the resolution of inflammation (FIG. 3) . Currently, no thera pies are available that can modulate NET formation or their activity.
The metabolic regulatory enzyme AMPactivated kinase (AMPK) contributes to the control of gout by its modulatory effects on IL1β and growthregulated α protein (also known as CXCL1) secretion by macro phages, and might serve as a sensor that links metabolic changes to the inflammatory response in gout. AMPK levels are regulated by multiple factors including exer cise and hypoxia, and affect cellular metabolism of lipids and glucose 57 . The addition of a pharmaco logical AMPK activator inhibited MSU crystal mediated inflammation both in macrophages and in mice 58 . Moreover, mice deficient for the αchain of AMPK had reduced inflammation compared with wildtype mice. AMPK levels were also increased by administration of lowdose colchicine in macrophages treated with MSU crystals, suggesting that the effects of colchicine on AMPK might contribute to its ability to inhibit the secretion of IL1β 58 .
Antiinflammatory cytokines also contribute to the resolution of the acute inflammatory process. In animal models, the addition of exogenous transforming growth factor β1 (TGFβ1) reduced experimental inflammation 59 ; in patients with gouty arthritis, TGFβ1, IL10 and IL1Ra were increased in the synovial fluid and were associated with the spontaneous resolution of acute gouty arthri tis 60 . Other factors might also contribute to the timely resolution of inflammation in gout. For example, the pro tein annexin A1, a potential inhibitor of phospholipase A2, decreases inflammation and promotes resolution in mouse models of gout 61 .
Comprehensive studies interrogating host and environ mental factors influencing inflammation in humans have shown that seasonal variation in α1antitrypsin (AAT) concentration affects cytokine production in patients with gout 62 . AAT, a member of the serpin superfamily that inhibits many serine proteases, was found to inhibit IL1β production upon treatment with MSU crystals in mice 63 . Circulating levels of AAT are at their highest in February and their lowest in the summer months. By contrast, retrospective studies have shown that gout peaks in the spring and summer 64 , when AAT concentration is at the lowest and IL1β production is at the highest. These findings suggest that AAT is a negative regulator of gouty inflammation 62 . Understanding how this seasonally reg ulated factor influences inflammation is an exciting new area of research. In particular, it would be interesting to understand how AAT influences the duration and intensity of gouty episodes.
Targeting inflammatory pathways
Treating gout requires two complementary approaches: one aimed at lowering levels of uric acid and the other aimed at reducing inflammation. NSAIDs, colchicine and glucocorticoids are commonly used and are effective in relieving the pain and inflammation of an acute attack; however, insights into the biology of inflammation open the way to new therapeutic strategies (FIG. 4) .
Modulators of the NLRP3 inflammasome
As the NLRP3 inflammasome is a key component in the response to MSU crystals, strategies that impede its activation or affect its activity could reduce gouty inflammation. Interestingly, colchicine blocks MSU crystalmediated NLRP3 activity in macrophages 15 , probably by inhibiting microtubuledriven rearrange ment of mitochondria following the engagement of NLRP3 with MSU crystals 65 .
Other molecules that target key steps in NLRP3 assem bly affect inflammation. βHydroxybutyrate suppresses inflammasome activation in response to MSU crystals 66 . This ketone body is produced in the liver of mammals during nutrient deprivation. Hence, starvation attenu ates caspase1 activation and IL1β secretion in mouse models of caloric restriction 66 . Similarly, a ketogenic diet protects rats from MSU crystalmediated gouty flares 67 . Mechanistically, βhydroxybutyrate has been proposed to inhibit potassium efflux upstream of NLRP3 and to directly affect inflammasome assembly 66 . However, a possible effect on priming has also been suggested 67 .
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Multiple studies in gout highlight the beneficial effects of compounds that inhibit ROS production and decrease oxidative stress. Epigallocatechin gallate, a potent anti oxidant polyphenol found in green tea, inhibits neutro phil infiltration and IL1β secretion in a mouse model of MSU crystalmediated peritonitis 68 . Morin, a natural flavonol, impairs MSU crystalinduced inflammation in mouse macrophages 69 .The gastroprotective drug rebami pide suppresses the MSU crystalmediated activation and release of IL1β in a human cell line 70 ; further studies are required to interrogate possible application of this drug in gout. Xanthine oxidase inhibitors used in patients to decrease serum urate levels also directly affect mito chondrial ROS production, thereby inhibiting MSU crystalmediated inflammasome activation 71 . Inhibiting ROS production or potassium efflux are rather nonspecific strategies that could have undesirable effects. Identification of more specific NLRP3 inhibi tors could, therefore, present more suitable therapeutic options for gout. For example, MCC950 (also known as CP456,773 or CRID3) has emerged as a potential drug of interest. This drug is a diarylsulfonylurea containing compound that was initially identified as an inhibitor of extracellular ATPmediated maturation of IL1β 72 . This discovery preceded the initial description of the inflammasome and the identification of NLRP3 as the main sensor of extracellular ATP signals. Subsequently it was demonstrated that MCC950 specifically inhib its the NLRP3 inflammasome 73 . This drug blocks NLRP3induced ASC oligomerization in mouse and human macrophages without affecting the activation of NLRP1, AIM2 or NLRC4 inflammasomes. The effects of several NLRP3 activators, including MSU crystals, were inhibited by MCC950 73, 74 , indicating that the drug might directly act on a conserved NLRP3activating mechanism; however, exactly how this drug affects NLRP3 activation is not yet clear.
Inhibitors of IL-1β maturation
Considerable effort has been made to develop specific caspase1 inhibitors. VX765, an orally available pro drug, is the best studied of these inhibitors. This drug is rapidly hydrolysed by plasma and liver esterases into a potent and selective inhibitor of caspase1 75 . In a mouse model of collageninduced arthritis, VX765 ameliorated the severity and progression of disease 76 . The caspase1 inhibitor pralnacasan also decreases IL1β production and cartilage damage in mice with streptococcal cell wall (SCW)induced arthritis, a model of chronic destructive joint inflammation 77 . However, the effects of caspase1 inhibitors in gout have not been explored. Of particular importance will be the specificity of the inhibitor for caspase1, as caspases share a highly conserved catalytic core and offtarget inhibition of apoptotic caspases could cause undesirable consequences.
Consistent with the findings indicating that AAT inhibits inflammation in gout 62 , a recombinant human AAT-Fc fusion protein was found to be effective in a mouse model of gouty arthritis 63 . AAT can modulate inflammation at multiple levels, and whether the effects observed in the gout model are directly caused by the inhibition of IL1β processing is unclear. Nonetheless, these data indicate that AAT-Fc, and possibly other serine protease inhibitors, could be of interest for the treatment of gout attacks.
IL-1 inhibitors
The evidence for the clinical efficacy of IL1 inhibition in acute gout has been reviewed elsewhere 37 . Two IL1 inhib itors, canakinumab and anakinra, are currently available 
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Orally available drug: IL1 inhibition can relieve the acute symptoms of gout in patients who have not responded to conventional treatments or in whom the use of NSAIDs, colchicine or glucocorticoidssteroids are contraindicated. Although IL1 inhibition is not recommended as a firstline anti inflammatory treatment, the results from clinical trials of canakinumab and cohort studies of patients who have received anakinra as treatment for acute flares showed a rapid onset of pain relief, with responses observed in nearly all treated patients 37 . Patients who had subsequent flares responded equally well when treated again with canakinumab 78 and, in our personal experience, ana kinra is also effective when given for recurrent flares. In patients with severe renal and cardiac impairment, a clinical situation that commonly makes the choice of acute therapy difficult, the use of IL1 inhibition has not been formally assessed in clinical trials; however, no severe adverse effects have been reported in case series 37 .
In the clinical trials involving canakinumab, a significant reduction of gout flares was seen for up to 6 months, with canakinumab treatment also reducing gout flares at the start of uratelowering therapy; however, the drug is not registered to reduce gout flares on starting therapy. As antiIL1 drugs have not been tested in large numbers of patients, their use is restricted to patients who have 'difficult to treat' disease and their safety with respect to infectious complications needs to be considered when they are prescribed.
Conclusions
The past 12 years have shown considerable progress in our understanding of the mechanisms of inflammation and the role of innate immune sensors in gout; however, several questions remain unanswered, with three areas being of particular interest. Firstly, the detailed specific mechanism by which NLRP3 is activated upon exposure to MSU crystals is still unclear. One emerging possibility is that NLRP3 acts as a guardian of cellular integrity by detecting perturbations triggered when innate immune cells attempt to engulf large particulates 79 . This concept would suggest that the size, and possibly the chemical nature and shape, of those particulates (including MSU crystals) could affect immune responses. Secondly, caspase1independent mechanisms of IL1 production, including which proteases are engaged and what triggers their activation, are still poorly understood. In this con text it would be important to understand at what stage of the response these pathways contribute to the inflamma tory phenotype and what are the cell types orchestrating this inflammasomeindependent response. Finally, the mechanisms that initiate gouty attacks in patients who have persistent MSU crystal deposits are a key area of interest. Whether specific initiating mechanisms contrib ute to triggering the inflammatory reaction, possibly by acting on priming signalling, or whether a decrease in the negative regulation of NLRP3 engagement promotes the inflammatory cascade, remains unclear. A better under standing of these processes might identify potential spe cific therapeutic strategies that will make the prevention and management of gout more effective and specific. The study of this old disease has provided us with a greater understanding of inflammatory pathways; solving the remaining questions still bears enormous potential for new discoveries of pathways and treatments that might have implications in several inflammatory diseases. 
